U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07684313) titled 'TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)' on June 29.
Brief Summary: TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.
Study Start Date: Aug., 2026
Study Type: OBSERVATIONAL
Condition:
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Tricuspid Valve Disease
Intervention:
DEVICE: Edwards TRIFORMIS RESILIA heart valve
Surgical replacement of the tricuspid valve with the...